Long Grove Pharma Unveils Premix Norepinephrine

Long Grove Pharmaceuticals has introduced a new ready-to-use Norepinephrine solution in 0.9% Sodium Chloride, aimed at enhancing the reliability and safety of critical patient care. Available now is the 16 mg/250mL (64 mcg/mL) concentration, with additional strengths of 4 mg/250mL (16 mcg/mL) and 8 mg/250mL (32 mcg/mL) expected by early summer. This innovation brings significant benefits to the healthcare sector, offering a stable shelf life of 24 months at room temperature and usability for up to seven days after the foil overwrap is removed.

The introduction of this ready-to-use premixed Norepinephrine addresses a crucial need in the fragile critical care supply chain. Hospital pharmacies can now redirect their limited resources to more pressing patient needs, thanks to the convenience and safety of this manufactured solution.

Peter Karas, Chief Commercial Officer of Long Grove Pharmaceuticals, expressed satisfaction at contributing to alleviating some of the daily stresses faced by hospital pharmacy staff. After extensive consultations with customers over the past six months, Karas highlighted the supportive feedback received, underscoring the demand for a safe and convenient premixed Norepinephrine solution.

Norepinephrine in 0.9% Sodium Chloride Injection is specifically indicated for raising blood pressure in adults experiencing severe, acute hypotension. It is a critical medication frequently used in intensive care units.

Long Grove Pharmaceuticals was founded in 2019 by Water Street Healthcare Partners and operates under Capstone Development Services, LLC. The company boasts a robust portfolio of specialized drug formulations, developed in collaboration with leading pharmaceutical and medical device companies. This strategic approach aims to boost hospital pharmacy efficiency and elevate patient care standards.